138 related articles for article (PubMed ID: 21699015)
1. Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo.
Machado MC; Bellodi-Privato M; Kubrusly MS; Molan NA; Tharcisio T; de Oliveira ER; D'Albuquerque LA
J Exp Ther Oncol; 2011; 9(2):85-92. PubMed ID: 21699015
[TBL] [Abstract][Full Text] [Related]
2. Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells.
Li X; Zhu Y; He H; Lou L; Ye W; Chen Y; Wang J
Biochem Biophys Res Commun; 2013 Jun; 436(2):259-64. PubMed ID: 23726914
[TBL] [Abstract][Full Text] [Related]
3. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells.
Greenblatt DY; Vaccaro AM; Jaskula-Sztul R; Ning L; Haymart M; Kunnimalaiyaan M; Chen H
Oncologist; 2007 Aug; 12(8):942-51. PubMed ID: 17766653
[TBL] [Abstract][Full Text] [Related]
5. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
Cui W; Yu CH; Hu KQ
Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
[TBL] [Abstract][Full Text] [Related]
7. Baclofen, a GABAB receptor agonist, inhibits human hepatocellular carcinoma cell growth in vitro and in vivo.
Wang T; Huang W; Chen F
Life Sci; 2008 Feb; 82(9-10):536-41. PubMed ID: 18222491
[TBL] [Abstract][Full Text] [Related]
8. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
Xia Q; Sung J; Chowdhury W; Chen CL; Höti N; Shabbeer S; Carducci M; Rodriguez R
Cancer Res; 2006 Jul; 66(14):7237-44. PubMed ID: 16849572
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis.
Koyama M; Izutani Y; Goda AE; Matsui TA; Horinaka M; Tomosugi M; Fujiwara J; Nakamura Y; Wakada M; Yogosawa S; Sowa Y; Sakai T
Clin Cancer Res; 2010 Apr; 16(8):2320-32. PubMed ID: 20371690
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors induced differentiation and accelerated mineralization of pulp-derived cells.
Duncan HF; Smith AJ; Fleming GJ; Cooper PR
J Endod; 2012 Mar; 38(3):339-45. PubMed ID: 22341071
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line.
Sanaei M; Kavoosi F; Roustazadeh A; Shahsavani H
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2507-2510. PubMed ID: 30256044
[TBL] [Abstract][Full Text] [Related]
12. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
[TBL] [Abstract][Full Text] [Related]
13. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells.
Tatebe H; Shimizu M; Shirakami Y; Sakai H; Yasuda Y; Tsurumi H; Moriwaki H
Cancer Lett; 2009 Nov; 285(2):210-7. PubMed ID: 19520494
[TBL] [Abstract][Full Text] [Related]
14. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.
Gao D; Xia Q; Lv J; Zhang H
Int J Urol; 2007 Sep; 14(9):838-45. PubMed ID: 17760752
[TBL] [Abstract][Full Text] [Related]
15. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.
Höti N; Chowdhury W; Hsieh JT; Sachs MD; Lupold SE; Rodriguez R
Mol Ther; 2006 Dec; 14(6):768-78. PubMed ID: 16990052
[TBL] [Abstract][Full Text] [Related]
17. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
Thelen P; Schweyer S; Hemmerlein B; Wuttke W; Seseke F; Ringert RH
Int J Oncol; 2004 Jan; 24(1):25-31. PubMed ID: 14654937
[TBL] [Abstract][Full Text] [Related]
18. Valproic acid exhibits biphasic effects on apoptotic cell death of activated lymphocytes through differential modulation of multiple signaling pathways.
Chen Q; Ouyang DY; Geng M; Xu LH; Zhang YT; Wang FP; He XH
J Immunotoxicol; 2011; 8(3):210-8. PubMed ID: 21457087
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma.
Angelucci A; Muzi P; Cristiano L; Millimaggi D; Cimini A; Dolo V; Miano R; Vicentini C; Cerù MP; Bologna M
Prostate; 2008 May; 68(6):588-98. PubMed ID: 18288684
[TBL] [Abstract][Full Text] [Related]
20. Synergism of hydroxyapatite nanoparticles and recombinant mutant human tumour necrosis factor-alpha in chemotherapy of multidrug-resistant hepatocellular carcinoma.
Li G; Dong S; Qu J; Sun Z; Huang Z; Ye L; Liang H; Ai X; Zhang W; Chen X
Liver Int; 2010 Apr; 30(4):585-92. PubMed ID: 19780956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
